Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Trends Pharmacol Sci. 2020 Nov 28;42(1):7–18. doi: 10.1016/j.tips.2020.11.003

Figure 4.

Figure 4.

Efficacy of iron(II)-targeted forms of FDA-approved MEK inhibitor cobimetinib. A. Structure of TRX-DRUG conjugates such as TRX-COBI, which releases free cobimetinib upon reaction with Fe2+. B. Tumor volume over time in mice bearing KRAS lung adenocarcinoma and treated with vehicle, SHP2 inhibitor + cobimetinib, or SHP2i + TRX-COBI at equivalent, equimolar doses. C. Phospho-ERK staining of tumor in spleen from animals studied in panel B, indicating selective activation of TRX-COBI in tumor. Unpublished data reproduced from bioRxiv 2020.05.12.088971.